In models of myocardial ischemia–reperfusion, RLN-2 treatment lowers neutrophil infiltration, reduces myeloperoxidase (MPO) activity, decreases lipid peroxidation products such as malondialdehyde (MDA), and helps maintain calcium homeostasis [74]. Here, MPO is linked to myocardial ischemia.